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ABSTRACT
Aberrant glycosylation plays a fundamental role in key pathological steps of 
tumour development and progression. Glycans have roles in cancer cell signalling, 
tumour cell dissociation and invasion, cell-matrix interactions, angiogenesis, 
metastasis and immune modulation. Aberrant glycosylation is often cited as a 
‘hallmark of cancer’ but is notably absent from both the original hallmarks of cancer 
and from the next generation of emerging hallmarks.  This review discusses how 
glycosylation is clearly an enabling characteristic that is causally associated with the 
acquisition of all the hallmark capabilities. Rather than aberrant glycosylation being 
itself a hallmark of cancer, another perspective is that glycans play a role in every 
recognised cancer hallmark.
INTRODUCTION
The hallmarks of cancer were originally outlined 
in 2000 and comprise six biological capabilities acquired 
during the multi-step development of cancer that allow 
cancer cells to survive, proliferate and disseminate [1]. 
As cells evolve progressively to a neoplastic state they 
acquire a succession of these hallmarks to allow them 
to become tumourigenic and ultimately malignant. The 
hallmarks include: sustaining proliferative signalling, 
evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, and 
activating invasion and metastasis [1]. Underlying theses 
hallmarks are genome instability and inflammation which 
contribute to multiple hallmark functions [1, 2]. In 2011, 
more than a decade after the publication of the original 
cancer hallmarks paper, the next generation of cancer 
hallmarks were published, and two emerging hallmarks 
were proposed: reprogramming of energy metabolism 
and evading immune destruction [3]. The next generation 
of cancer hallmark traits recognised the ‘tumour 
microenvironment’, or the cellular environment in which 
the tumour exists, as contributing to the acquisition of 
hallmark traits, adding another dimension of complexity 
to cancer progression [3].
Aberrant glycosylation in cancer was first described 
more than 45 years ago [4], and since then it has been well 
documented that fundamental changes in the glycosylation 
patterns of cell surface and secreted glycoproteins occur 
during malignant transformation and cancer progression. 
Many of the first cancer-specific antibodies identified 
were directed against oncofetal antigens expressed on 
embryonic and tumour cells but not in adult tissues [5]. 
The importance of glycosylation in cancer is further 
emphasised by that fact that the majority of FDA-approved 
tumour markers are glycoproteins or glycan antigens [6-
8]. The expression of cancer associated glycans such as 
sialyl-LewisX (SLeX), Thomsen-nouvelle antigen (Tn), 
and sialyl-Tn (sTn) antigen have been detected in virtually 
every cancer type [9].
Growing evidence supports crucial roles for 
glycosylation during all steps of tumour progression, 
and it is well established that glycans regulate tumour 
proliferation, invasion, metastasis and angiogenesis 
[10, 11]. Aberrant glycosylation is frequently cited as a 
hallmark of cancer [11-15], but is notably absent from 
both the original hallmarks paper [1] and from the next 
generation hallmarks [3]. The goal of this review is to 
highlight glycosylation as a mechanistic concept integral 
to the recognised hallmark traits. Unique to our discussion 
is our focus on how glycosylation enables acquisition of 
all the 10 currently accepted hallmarks of cancer cells. 
GLYCOSYLATION
Glycosylation is the enzymatic process that produces 
glycosidic linkages of saccharides to other saccharides, 
lipids or proteins [11]. Glycosylation is a frequent and 
well known post-translational protein modification, and 
probably much more frequent than phosphorylation. The 
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glycome, or complete pattern of glycan modifications 
in a cell or tissue, is assembled by the synchronised 
action of numerous glycan modifying enzymes. These 
enzymes include glycosyltransferases and glycosidases 
that glycosylate various complex carbohydrates such as 
glycoproteins, glycolipids and proteoglycans. How much a 
given protein is glycosylated depends on the presence and 
frequency of glycosylation sites in the protein sequence, 
as well as the expression and activities of specific 
glycosylation enzymes within the cell or tissue [16]. 
The two most common mechanisms by which 
glycans are linked to proteins are O-linked glycosylation 
and N-linked glycosylation. In O-linked glycosylation, 
sugars are added incrementally to the hydroxyl oxygen 
of serine, threonine residues [17]. A common type 
of O-linked glycosylation is initiated via addition of 
GalNAc, which can then be extended into various different 
structures. Other types of O-glycans include those 
attached via O-mannose, and the β-N-acetylglucosamine 
(O-GlcNAc) [18-20]. In N-linked glycosylation 
preassembled blocks of 14 sugars are transferred co-
translationally via the amide group of an asparagine 
residue and are then further processed [21]. Addition of 
O-GlcNAc (O-GlcNAcylation) occurs almost exclusively 
within the cell as an alternative to phosphorylation, while 
N- and O-glycans tend to be found at the cell surface as 
secreted entities, meaning that intra-cellular proteins may 
be effected by O-GlcNAcylation while interactions at the 
cell surface often involve N- glycans and O-glycans [17, 
20, 22].
Alterations in glycan composition can aid in 
various stages of cancer progression. The mechanisms 
that produce altered glycan structures in cancer cells 
remain poorly understood, but are believed to involve 
changes in epigenetics, genetic mutations, misregulated 
expression of glycosyltransferase and chaperone genes, 
and mislocalisation of glycosyltransferases [23-26]. 
SUSTAINING PROLIFERATIVE SIGNALLING
A fundamental trait of cancer cells is their ability to 
maintain chronic proliferation [1]. It is well established 
that glycan expression can play a role in maintaining 
proliferative signalling. O-GlcNAc modification of 
proteins has been shown to regulate important cell 
proteins involved in cell cycle progression including 
the transcription factor forkhead protein M1 (FoxM1), 
cyclin D1 [27], and cMYC [28]. Increased MYC 
O-GlcNAcylation can compete with phosphorylation, 
stabilising MYC protein and contributing to oncogenesis 
[28]. The degree of N-glycan branching can also modulate 
the activity and signalling of growth factor receptors, 
and can contribute to proliferative signalling [29-32]. 
Numerous growth factor receptors including EGFR, 
FGFR, PDGF, MET and IGFR are known to be regulated 
by glycosylation [33-35]. 
The extracellular matrix (ECM) imparts the 
spatial context for the signalling events of various 
cell surface growth factor receptors, and is composed 
of a dynamic and complex array of glycoproteins, 
collagens, glycosaminoglycans and proteoglycans [36]. 
Glycosylation has been shown to facilitate integrin 
dependent growth factor signalling to promote cell growth 
and survival [37, 38], and can also markedly modify the 
function and signalling of the multifunctional cell surface 
molecule CD44 [39, 40]. Ceramide glycosylation in the 
cell membrane can actively participate in maintaining 
cancer stem cells by activating c-Src signalling and 
β-catenin mediated upregulation of stem cell factors 
[41]. Proteoglycans also play a role in the biogenesis and 
recognition of exosomes (secreted vesicles of endosomal 
origin) which are involved in cell signalling [42]. 
EVADING GROWTH SUPPRESSORS
In addition to inducing and maintaining positively 
acting growth stimulatory signals, cancer cells must 
also overcome powerful programs that negatively 
regulate cell proliferation, many of which depend on the 
actions of tumour suppressor genes. The two canonical 
suppressors of proliferation, p53 and RB (retinoblastoma) 
proteins have both been documented to contain potential 
glycosylation sites, and their functions may be controlled 
by dynamic O-GlcNAc modification as well as by 
phosphorylation [43-45]. O-GlcNAcylation of p53 at 
residue Ser149 is thought to promote its tumour suppressor 
activity by inhibiting its phosphorylation on Thr155 [44, 
45]. Examples of gain of function p53 mutants have been 
widely described [46-48], and in this context it might be 
possible that O-GlcNAcylation induced stabilisation of 
gain of function mutant forms of p53 could amplify its 
pro-oncogenic activity [45]. 
DEREGULATING CELLULAR ENERGETICS
A key feature of cancer cells is a shift from oxidative 
phosphorylation to aerobic glycolysis [49]. Known as the 
‘Warburg effect’, this shift in metabolism is characterised 
by high rates of glucose and glutamine uptake to cope 
with the increased energetic and biosynthetic needs of the 
tumour. The abundance of glucose contributes to increased 
glycolysis and increased flux through metabolic pathways 
such as the hexosamine biosynthetic pathway (HBP). 
The end product of the HBP is UDP-GlcNAc which is 
a critical metabolite used in O-GlcNAcylation and in 
both N- and O-glycosylation [50]. O-GlcNAc is elevated 
in various types of cancer and has itself been described 
as a hallmark of cancer [45, 51]. O-GlcNAcylation can 
act as a ‘nutritional sensor’, and may provide feedback 
signals that modulate metabolism in response to changing 
nutrient status [20, 52, 53]. Several studies have suggested 
that hyper-O-GlcNAcylation is linked to cancer-associated 
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metabolic reprogramming [54]. O-GlcNAc can modify 
a number of glycolytic enzymes [55-57], including 
phosphofructokinase 1 (PFK1) which catalyses the rate 
limiting step in glycolysis [57]. O-GlcNAcylation may 
also play a role in metabolic reprogramming by regulating 
transcription factors [58, 59] and c-MYC stability [28].
RESISTING CELL DEATH
Programmed cell death by apoptosis serves as a 
natural mechanism to prevent cancer development, and 
a hallmark of cancer is the ability of malignant cells 
to evade apoptosis [1, 60]. Glycans play a key role in 
many of the processes leading to cell death, and can 
control intracellular signals and extracellular processes 
that promote the initiation, execution and resolution of 
apoptosis [61]. Cancer cells often use their glycosylation 
machinery to modify glycans on cell death receptors, 
enabling them to resist apoptosis [61]. Glycosylation 
can modulate the function of death receptors including 
Fas (CD95) and TNFR1 (tumour necrosis factor receptor 
1) [62, 63]. The glycosylation of death receptors and 
their canonical ligands may critically regulate apoptosis 
by disrupting ligand-receptor interactions [64, 65], 
modulating the formation of signalling complexes [66], 
and influencing ligand secretion from effector cells [67]. 
The apoptotic machinery can be positively or negatively 
regulated through interactions between glycosylated 
receptors and glycan binding proteins [68]. Lectins are a 
family of carbohydrate binding proteins that specifically 
recognise glycans. Galectin-3 association with Fas can 
repress apoptotic signals [69], and increase tumour cell 
survival [70, 71].
Cellular accumulation of the glycoshingolipid GD3 
contributes to mitochondrial damage and plays a key 
role in apoptosis [72]. GD3 expression is upregulated 
in neoplastic cells where it regulates tumour invasion 
and survival [73]. Although an increase in GD3 would 
normally induce apoptosis, in glioblastomas addition of 
an acetyl group to the terminal sialic acid (to produce 
9-O-acetyl GD3) makes GD3 unable to induce apoptosis, 
thus promoting tumour survival [74]. Ceramide 
accumulation also plays a role in programmed cell death 
[75]. The glucosylceramide synthase (GCS) enzyme can 
glycosylate ceramide and blunt its pro-apoptotic activity 
in cancer cells [76]. 
ENABLING REPLICATIVE IMMORTALITY
An essential property of cancer cells is to overcome 
the normal cellular senescence process resulting from the 
shortening of telomeres. Telomerase activation is a critical 
step in carcinogenesis and is thought to occur in over 90% 
of cancers [77]. Transcriptional reactivation of the human 
telomerase reverse transcriptase (hTERT) gene is a major 
mechanism of cancer-specific activation of telomerase. 
Although to date there is no evidence linking glycans 
to telomerase activation, and glycosylation of hTERT 
has so far not been reported, there is indirect evidence 
linking glycosylation to telomerase activation through 
the glycosylation of the transcription factor c-MYC. 
C-MYC is a direct mediator of telomerase activation and 
can directly induce hTERT gene expression [78, 79]. The 
c-MYC protein is known to be glycosylated [80], and 
has been shown to be stabilised by modification with 
O-GlcNAc [28]. Levels of O-GlcNAcylation are up-
regulated in various types of cancer [45, 51], as are some 
of the enzymes involved in the hexosamine biosynthesis 
pathway [81]. Future studies will help determine 
whether O-GlcNAc mediated stabilisation of c-MYC can 
indirectly influence telomerase activation and contribute to 
replicative immortality.
ACTIVATING INVASION AND METASTASIS
The development of malignant tumours requires 
the ability of tumour cells to overcome cell-cell adhesion 
and then invade surrounding tissue. Mounting evidence 
suggests that certain glycan structures can affect tumour 
cell invasiveness, including the ability to disseminate 
through the circulation and metastasise into distant 
organs [9]. Cancer cells often have high levels of 
sialylated glycans [82], which are often associated with 
malignancy and poor prognosis in patients [83-86]. 
Increased sialylation can increase local negative charges 
to physically disrupt cell-cell adhesion, and promote 
detachment from the tumour mass through electrostatic 
repulsion [87]. Consistent with this, expression of the 
cancer-associated sTn-antigen reduces cell adhesion in 
prostate cancer and increases migration and invasion in 
breast and gastric carcinoma [88-93]. Similarly, ectopic 
expression of the sialyltransferase ST6GAL1 in breast 
cancer cells has been shown to reduce cell adhesion 
[94]. Cancer cells characteristically express proteins with 
truncated O-glycan structures that are thought to be due 
to mutations or epigenetic silencing of the COSMC gene 
[95, 96], or to increased expression of ST6GalNAc1 [88]. 
The immature O-glycophenotype of cancer cells has been 
directly linked to cancer cell growth and invasion [95].
Glycosylation can also influence the activity 
and localisation of proteins involved in cell adhesion, 
including the transmembrane glycoprotein E-cadherin. 
Over-expression of the enzyme MGAT5 in gastric cancer 
cells induces E-cadherin mislocalisation from the cell 
membrane into the cytoplasm [97, 98]. MGAT5 catalyses 
β1,6GlcNAc branching of N-glycans on E-cadherin, 
which in turn leads to non-functional adherens junctions, 
impairs cell-cell adhesion and downstream signalling, 
and contributes to invasion and metastasis [22, 97-
101]. Downregulation of the enzyme MGAT3 in mouse 
mammary tumours increases cell migration and metastasis 
but genetic background may modify this effect in human 
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breast cancer cells [22, 102, 103]. MGAT3 catalyses the 
addition of bisecting GlcNAc to complex N-glycans and 
is thought to influence interactions with galectins, and to 
regulate the function of some glycoproteins, including 
growth factor receptors and some adhesion molecules 
[22].
As well as reducing cell-cell adhesion and aiding 
dissociation from the primary tumour, glycans can also 
promote the adhesion of tumour cells. The SLeX antigen 
is upregulated in several types of cancer [17, 104], and 
can promote adhesion of tumour cells to endothelial cells 
through interactions with selectins, in this way mediating 
the initial steps in metastasis [11, 82]. Galectin-3 regulates 
the dynamics of N-cadherin [29], and Galectin-1 binding 
to CD44 and CD326 can promote attachment to the ECM 
and endothelial cells [105]. 
The sialytransferase ST6GalNAc2 has been 
identified as a metastasis suppressor in breast cancer 
cells which is linked to patient survival [106]. Loss 
of ST6GalNAc2 was found to alter the profile of 
O-glycans on the cell surface and facilitate Galectin-3 
binding, leading to an increased metastatic burden 
[106]. Glycosylation enzymes may also play a key role 
in mediating cancer cell passage through the blood brain 
barrier. GALNT9 (an initiator of O-glycosylation) is 
frequently epigenetically dysregulated in breast tumours 
that metastasise to the brain [107]. The sialyltransferase 
ST6GalNAc5 is normally restricted to the brain, but its 
expression in breast cancer can specifically mediate 
metastasis to the brain, highlighting the role of cell-surface 
glycosylation in organ-specific metastatic interactions 
[108].
INDUCING  ANGIOGENESIS
Through inducing the process of angiogenesis, 
development of tumour associated neovasculature 
enables tumours to acquire nutrients and oxygen as well 
as the ability to remove metabolic waste including carbon 
dioxide. The development of vasculature involves growing 
new endothelial cells and their assembly into tubes 
(vasulogenesis), and the sprouting (angiogenesis) of new 
vessels from existing ones. In the adult the vasculature 
is largely quiescent, but during tumour progression an 
‘angiogenic switch’ is activated causing vasculature to 
continually sprout new vessels and aid tumour growth 
[109]. A distinct set of glycosylation related genes has 
been linked to the angiogenesis process [110, 111], and it 
has become increasingly evident that glycans are integral 
to different events in the angiogenesis cascade [112]. 
A key inducer of angiogenesis is vascular endothelial 
growth factor (VEGF), which signals via receptor tyrosine 
kinases (VEGFRs) and plays a pivotal role in angiogenesis 
during development and in cancer. Glycosylation of both 
VEGF and the VEGFRs is associated with angiogenesis. 
VEGF levels are upregulated by O-GlcNAcylation [113], 
and aberrant glycosylation of VEGFR can modulate 
its interaction with galectins and influence blood vessel 
growth [112]. Glycans also play a role in angiogenesis by 
regulating Notch signalling [114], maintaining endothelial 
cell survival [115], controlling vascular permeability 
[116], and mediating the connection of blood and 
lymphatic vessels [117]. Changes in cytokines, growth 
factors and hypoxic conditions have been shown to alter 
the endothelial glycome to facilitate binding of galectin-1 
and activate pro-angiogenic signalling pathways, raising 
the possibility that a glycosylation signature could be used 
to distinguish blood vessels at different stages of tumour 
progression [118].
Heparan sulfate (HS) proteoglycans are abundantly 
expressed in the developing and mature vasculature, and 
play a pivotal role in angiogenesis by facilitating the 
binding of cell surface pro-angiogenic growth factors 
[119-121]. HS proteoglycans have been described as 
‘heavy hitters in the angiogenesis arena’ [122], and can 
modulate angiogenesis by affecting the bioavailability and 
interaction of heparin-binding VEGFs with VEGFRs [123, 
124], and by interacting with anti-angiogenic factors such 
as endostatin [125]. In ovarian cancer HS has been shown 
to impact angiogenesis through EGF receptor signalling 
and influencing the expression of angiogenic cytokines 
[126].
GENOME INSTABILITY & MUTATION
Acquisition of the cancer hallmarks is made possible 
in part by the development of genomic instability in cancer 
cells which generates random mutations and chromosomal 
rearrangements. The accumulation of mutations can 
be accelerated by disrupting the surveillance systems 
that normally monitor genomic integrity. The tumor 
suppressor p53 has long been known to play a central 
role in maintaining a stable genome [127]. O-GlcNAc 
and O-phosphate modifications co-ordinately regulate 
p53 stability and activity [44], and a role for O-GlcNAc 
in the regulation of DNA damage signalling or repair 
has been suggested [128]. ATM, a key regulator of DNA 
damage repair is glycosylated, and studies have indicated 
a dynamic interplay between phosphorylation and 
O-GlcNAc in the regulation of the DNA damage pathway 
which could be linked to genomic instability in cancer 
[129]. 
TUMOUR PROMOTING INFLAMMATION
It has long been recognised that some tumours 
are densely infiltrated by cells of the immune system 
and thereby mirror inflammatory conditions in non-
neoplastic tissues [3, 130]. Historically, these immune 
responses were thought to reflect an attempt by the 
immune system to eradicate the cancerous cells, but 
there is now growing evidence that the response has 
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an unanticipated paradoxical effect to actually aid in 
tumorigenesis and cancer progression. Within the tumour 
microenvironment, inflammation can contribute to 
multiple hallmark capabilities [2, 3], and plays a role in the 
proliferation and survival of malignant cells, angiogenesis, 
metastasis, subversion of adaptive immunity, and 
response to hormones and chemotherapy [2, 131-134]. 
Genomic instability can also be induced by inflammatory 
mediators [2]. Changes in glycan composition are closely 
associated with inflammation [14], and suggest an intricate 
relationship between glycosylation and inflammation 
in cancer progression. The selectin proteins (E-, P- 
and L-Selectin) are associated with cancer metastasis 
[135], but also play a key role in the entry of circulating 
lymphocytes into peripheral lymph nodes and leukocyte 
emigration into inflamed tissues [14, 136]. The selectins 
bind sialylated and fucosylated glycans (such as SLex) 
which act as ‘endothelial zip codes’ for the homing of 
lymphocytes into inflammatory sites [137].
Emerging evidence suggests that key mediators 
in the inflammatory response may be regulated by 
glycosylation. NF-κB is a well-characterised orchestrator 
of inflammation which induces the expression of 
inflammatory cytokines [138]. The transcriptional activity 
of NF-κB can be regulated by O-GlcNAcylation [139], 
which is known to be upregulated in multiple cancer types 
[45]. Similarly, the pro-inflammatory molecule COX2 is 
also regulated by glycosylation [140], and the efficiency 
of some COX2 inhibitors is thought to be dependent on 
COX2 glycosylation state [141]. Interestingly, a diet 
derived sialic acid called N-glycolylneuraminic acid 
(Neu5Gc, found primarily in red meat) can be incorporated 
in human tissues. This can lead to the production of auto-
antibodies against Neu5Gc and subsequent tumour related 
inflammation via induction of ‘xenosialitis’[142].
As well as glycan involvement in the inflammatory 
response, the inflammatory microenvironment can also 
reciprocally mediate changes in the glycan composition 
of cells, which could contribute to tumour malignancy. 
Pro-inflammatory cytokines can increase the expression 
of glycosyltransferases involved in the biosynthesis of 
cancer-associated antigens in pancreatic and gastric cancer 
cell lines [143, 144].
Figure 1: Glycosylation is an enabling characteristic that is causally associated with the acquisition of all the cancer 
hallmark capabilities. 
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AVOIDING IMMUNE DESTRUCTION
Cancer immune surveillance is thought to inhibit 
carcinogenesis and is an important host protection 
process through which transformed cells are eliminated 
by immune effector cells. Growing evidence suggests that 
interactions between tumour specific glycans and lectins 
on immune cells are involved in modulating the tumour 
microenvironment [145]. Glycans regulate various aspects 
of the immune response and can interfere with the anti-
tumour response of the immune system, leading to the 
emergence of cancer cells resistant to the immune system 
[11, 146]. This process is mediated by various lectins that 
bind glycans and regulate immune processes [147, 148]. 
Galectins can modulate the immune and inflammatory 
responses and are thought to play a role in helping 
tumours escape immune surveillance [147, 149]. Siglecs 
(sialic acid-binding immunoglobulin-type lectins) are 
transmembrane proteins found on the surface of immune 
cells. Siglecs are thought to bind to specific glycans and 
may play a role in escaping immune surveillance in cancer 
[150]. For example, the alteration of cell surface glycans 
can modulate siglec-7 mediated cytotoxicity of NK cells 
and contribute to immune evasion [151]. Glycosylation of 
IgG is known to play a role in tumour immune surveillance 
and is being investigated as a diagnostic marker in several 
cancer types [152-155]. Targeting altered glycosylation 
using anticancer vaccines that target tumour associated 
antigens is an appealing option for cancer treatment [156, 
157]. 
CONCLUSIONS
The hallmarks of cancer comprise biological 
capabilities acquired during the multi-step development 
of cancer that allow cancer cells to survive, proliferate 
and disseminate [1]. Glycosylation is frequently cited as 
hallmark of cancer but was notably absent from both the 
original hallmarks and from the updated next generation 
cancer hallmarks. Here we argue that the process of 
glycosylation is an enabling characteristic that is causally 
associated with the acquisition of all the proposed cancer 
hallmark capabilities (Figure 1), and conversely that 
the glycan composition of cancer cells can in turn be 
influenced by the other hallmarks. Glycans have roles 
in cancer cell signalling, tumour cell dissociation and 
invasion, cell-matrix interactions, angiogenesis, metastasis 
and immune modulation. Recognition of the widespread 
applicability of glycosylation to the cancer hallmarks will 
increasingly affect the development of new means to treat 
human cancer.
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